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Simple Summary: The emergence of immunotherapy for cancer treatment bears considerable clinical
promise. The role of NK cells in tumor immunosurveillance and their potential for successful cancer
immunotherapy strategies is currently established. Specific focus is placed on the use of specialized
monoclonal antibodies against NK cell immune checkpoints (ICI). The recent discovery that also
helper ILCs express inhibitory IC suggests that these molecules might be also targeted on ILCs to
modulate their functions in the tumor microenvironment. Herein, we provide an overview of the
current knowledge on IC on NK cells and ILCs and we discuss how to target these innate lymphocytes
by ICI in both solid tumors and hematological malignancies. Overall, we believe that, in our near
future, immunotherapy protocols will need to be designed taking into account all ILCs, both cytotoxic
(NK) and non-cytotoxic (helper ILCs) ones, and most importantly, ILCs targeting should be tailored
according to the disease.
Abstract: Immune checkpoints refer to a plethora of inhibitory pathways of the immune system
that play a crucial role in maintaining self-tolerance and in tuning the duration and amplitude of
physiological immune responses to minimize collateral tissue damages. The breakdown of this
delicate balance leads to pathological conditions, including cancer. Indeed, tumor cells can develop
multiple mechanisms to escape from immune system defense, including the activation of immune
checkpoint pathways. The development of monoclonal antibodies, targeting inhibitory immune
checkpoints, has provided an immense breakthrough in cancer therapy. Immune checkpoint inhibitors
(ICI), initially developed to reverse functional exhaustion in T cells, recently emerged as important
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actors in natural killer (NK)-cell-based immunotherapy. Moreover, the discovery that also helper
innate lymphoid cells (ILCs) express inhibitory immune checkpoints, suggests that these molecules
might be targeted on ILCs, to modulate their functions in the tumor microenvironment. Recently,
other strategies to achieve immune checkpoint blockade have been developed, including miRNA
exploiting systems. Herein, we provide an overview of the current knowledge on inhibitory immune
checkpoints on NK cells and ILCs and we discuss how to target these innate lymphocytes by ICI in
both solid tumors and hematological malignancies.
Keywords: natural killer cells; innate lymphoid cells; immune checkpoint; immunotherapy; KIR;
PD-1; NKG2A; innate immunity; immune escape; miRNA
1. Introduction
Innate lymphocytes (ILs) are a heterogeneous group of non-B and non-T lymphocytes. Recent progress
in the understanding of their cytokine production, cytotoxic functions, and transcription factors involved
in their development has led to an improved classification of these cells into five distinct subsets, namely
natural killer (NK) cells, helper ILCs (i.e., ILC1s, ILC2s, ILC3s), and lymphoid tissue inducer (LTi) cells [1,2].
While NK cells represent the innate counterpart of CD8+ T lymphocytes, helper ILCs mirror
the CD4+ T helper lymphocytes [3]. NK effector-functions are finely tuned by an array of receptors
mediating either inhibitory or activating signals. The lack or reduced expression of self-human
leukocyte antigen (HLA)-I alleles, a frequent event in malignant cells, induces the NK-cell activation
and cytotoxicity through the release of perforin and granzymes as well as the rapid production of
Interferon (IFN)-γ and tumor necrosis factor (TNF)-α [3–6].
In humans, NK cells can be further subdivided into functionally distinct subsets based on
the surface expression of CD56 and CD16 that are differently distributed in healthy or inflamed
tissue [4,7–10].
Helper ILC1s, similarly to NK cells and Th1 cells, express T-bet, produce IFN-γ, and represent
potent effectors against infections, but are generally poorly cytotoxic [11,12].
Notably, a CD56+ILC1-like cell population with cytotoxic properties and sharing features with
both ILC1s and CD56bright NK cells has been recently described [13].
Similar to Th2 cells, ILC2s express high levels of GATA3 and are involved in the production of type
2 cytokines including interleukin (IL)-4, IL-5, IL-9, and IL-13, in response to IL-25 and IL-33 produced
by epithelial cells or other immune cells following parasite infections or allergen exposure [2,12,14].
In addition, ILC2s produce amphiregulin, a member of the epidermal growth factor that helps repairing
damaged tissues [15].
ILC3s are RORγt+ lymphocytes, mainly resident in the gut lamina propria, but also localized
in skin, lung, liver, and decidua, where they participate in tissue homeostasis at the steady state
and in protective immune responses against extracellular bacteria and fungi by secreting Th17
cytokines [16,17].
In addition to ILC3s, also LTi cells are able to produce IL-22 and IL-17 to initiate protective immune
responses against extracellular bacteria [18]. They are mainly involved in lymphoid organogenesis
during embryogenesis, but LTi-like cells have also been found in post-natal life, where they participate
in the development of T and B cells [19].
Among the innate lymphocytes, NK cells are undeniably the best-studied mediators of anti-tumor
innate immune responses. Indeed, NK cells are the most abundant innate lymphocytes and usually
their presence correlates with a better prognosis and a decreased metastatic potential in human
cancers [20,21]. Moreover, their ability to recognize and eliminate nascent transformed cells is
corroborated by the observation that individuals with a decreased natural cytotoxic activity have an
increased cancer risk [22].
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In addition to NK cells, several lines of evidence indicate that helper ILCs are increased at the
tumor site [23]. However, while NK cells possess a clear tumor-suppressive role in several cancers,
helper ILCs are emerging to have pro- and anti-tumor properties depending on the microenvironment,
probably because of their high plasticity and heterogeneity [24].
Furthermore, tumor cells can render all ILCs inefficient in controlling cancer initiation and
progression, by developing multiple mechanisms to favor immune evasion. Among them, the activation
of immune checkpoint (IC) pathways, through the expression of ligands for inhibitory receptors and
the modulation of inhibitory and activating receptor expression, represents one of the most attractive
targetable tumor-escape mechanisms to restore anti-tumor immunity [23].
As a matter of fact, the development of immune checkpoints inhibitors (ICIs), monoclonal
antibodies (mAbs) targeting inhibitory receptors, has provided an immense breakthrough in
cancer therapy.
Herein, we review the current knowledge on inhibitory checkpoints expressed on NK cells and
helper ILCs. Moreover, we provide a comprehensive overview on the recent insights to boost NK
cells against cancer by using ICI, which can act directly, through the binding to the specific inhibitor
receptor, or indirectly, by promoting antibody-dependent cell-mediated cytotoxicity (ADCC) (Table 1).
Table 1. Current evidence of immune checkpoint expressed in innate lymphocytes and their involvement
in cancer immunotherapy.










Kaposi sarcoma, PC, ovarian
and lung cancers [26–30], and
HL [31]
Use of anti-PD-1 or anti-PD-L1
improves the anti-tumor







(>PD-1 than circulating ILCs)
[33]
ILC2s and ILC3s in tumors of
the gastrointestinal tract
(>PD-1 than in the
paralesional tissue)
ILC3s in human malignant
pleural effusion [30]







all pediatric tumor types [34]
IPH2102 combined with
anti-PD-1 (nivolumab)












HL, NHL, MM NCT01592370Phase 1/2
375 participants
(active)
Cancers 2020, 12, 3504 4 of 25
Table 1. Cont.








Advanced solid tumors NCT01714739Phase 1/2
337 participants
(completed)
















































MSS-CRC NCT04145193phase 2 Withdrawn

































































Cancers 2020, 12, 3504 5 of 25
Table 1. Cont.















Advanced malignancies NCT02608268phase 1/2
252 participants
(active)
AML or high risk MDS NCT03066648phase 1
235 participants
(recruiting)
ILC TIM-3+ ILC3s were found inthe decidua [17]
TIGIT
NK
Colon cancer patients and
tumor models [42]
TIGIT blocking was suggested
as a potent strategy to increase
graft versus leukemia effect in


































Urothelial carcinoma NCT03869190phase 1/2
385 participants
(recruiting)
Pancreatic adenocarcinoma NCT03193190phase 1/2
290 participants
(recruiting)




































Advanced solid tumors NCT03628677phase 1
66 participants
(recruiting)
Lung cancer NCT04262856phase 2
150 participants
(recruiting)
ILC ILC1 and splenic ILC3 [44]
Cancers 2020, 12, 3504 6 of 25
Table 1. Cont.






































Solid tumors NCT02720068phase 1
576 participants
(recruiting)




TSR-033 or combined with
anti-PD-1



































Melanoma [45] NCT02676869phase 1
24 participants
(completed)















from ILC3s isolated from first
trimester decidual tissue [17]
and in a subset of ILC2s
in vivo expanded with
IL-25 [47]
KLRG1 transcripts identified
in ILC2s in lung and colorectal
cancer [20]
CTLA-4 ILC
Expression of CTLA-4 in
tumor associated ILC1s and
ILC2s [33,46]
AML: acute myeloid leukemia; CLL: Chronic lymphocytic leukemia; mAb: monoclonal antibody; MDS:
myelodisplastic syndrome; MM: multiple myeloma; MSS-CRC: microsatellite-stable colorectal cancer; NSCLC:
non-small cell lung cancer; PC: peritoneal carcinomatosis; SCCHN: squamous cell carcinoma of the head and neck;
SCLC: small cell lung cancer.
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2. NK Cells
2.1. PD-1
PD-1 is an inhibitory receptor originally discovered on T cells and playing an important role in
maintaining peripheral tolerance and T-cell homeostasis. However, its interaction with PD-ligands
(PD-L1 and PD-L2), that may be expressed on tumor cells, can inhibit T-cell function, contributing
to immune escape. For this reason, PD-1 has become one of the most investigated targets for cancer
immunotherapy. Although most research has centered on inhibiting PD-1 on T cells, the interest in
understanding its role also in NK cells is emerging.
Indeed, PD-1 is brightly expressed on a discrete subset of circulating and fully mature
(KIR+NKG2A−CD57+) NK cells belonging to CD56dim and (if present) to CD56neg subsets, from
one-fourth of healthy individuals (HDs) seropositive for human cytomegalovirus (HCMV). Importantly,
the analysis at different time points of the PD-1+ cell subset in given individuals indicated that this
population remains stable over time [26].
As a matter of fact, higher proportions of PD-1+ CD56dim NK cells can be detected in patients
affected by different tumors, including Kaposi sarcoma, peritoneal carcinomatosis (PC), and ovarian
cancer (OC) [26–30]. Moreover, PD1+ NK cells have been found in Hodgkin lymphoma (HL), but its
expression is mainly confined to the CD56bright subset. The expression of PD-1 on NK cells has been
also found to have a possible unfavorable prognostic role, being particularly increased in high-grade
PC patients [31].
In addition to its surface expression, recent studies showed that human NK cells display an
intracytoplasmic pool of PD-1-mRNA and PD-1-protein [48].
Of note, since the size of the PD-1+ NK cell subset is enriched in the tumor microenvironment, as
compared to peripheral blood (PB) of the same patient, it is conceivable that, soluble factors and/or
cells in the tumor microenvironment can induce PD-1 expression [26,49]. In this regard, a key role for
HCMV in PD-1+ NK subset induction was suggested [26] and PD-1 expression in spleen NK cells was
selectively induced by endogenous glucocorticoids in response to murine CMV infection [49]. Recently,
a correlation between the presence of glucocorticoids together with high levels of pro-inflammatory
cytokines (i.e., IL-12, IL-15, and IL-18) and de novo expression of PD-1 on CD56bright NK cells has been
established [50].
Importantly, the use of anti-PD-1 or anti-PD-L1 mAbs improves the anti-tumor activity of NK
cells against PD-L1/2+ tumor cells [25,26,28,51]. This is clinically relevant for patients with tumors
displaying a T-cell-resistant (i.e., HLA-I−) phenotype. In order to get an amplified and more effective
response by both NK and T cells, several immunotherapeutic trials focused on the blockade of
multiple ICs shared by these immune cells are ongoing (Table 1). In this regard, a combination of
monalizumab (anti-NKG2A) and durvalumab (anti-PD-L1) has been evaluated in a first-in-human
dose-escalation/dose-expansion phase I trial in patients with metastatic microsatellite-stable colorectal
cancer (MSS-CRC). The rationale of this study was supported by preclinical models (https://www.
innate-pharma.com/sites/default/files/180205asco_15poster_09.pdf) and was based on the hypothesis
that the inhibition of NKG2A might improve the efficacy of PD-1/PD-L1-disrupting agents. This study
included 40 patients in the MSS-CRC expansion cohort. The treatment was well-tolerated; 3 responses
and 11 disease stabilizations were observed, with a disease control rate of 24% at 16 weeks [32].
2.2. KIRs
Killer immunoglobulin-like receptors (KIRs) can be divided into two categories depending on the
number of extracellular Ig-like domains (two for the KIR2D and three for the KIR3D), and depending on
the cytoplasmatic tail which dictates the function of the molecule into: Inhibitory KIRs (iKIR), with a long
(L) cytoplasmic tail with two tyrosine-based inhibitory motifs (ITIMs); activating KIRs (aKIR), with a
short (S) cytoplasmic tail containing a charged amino acidic residue associated to the KARAP/DAP12
adaptor molecule, bearing immunoreceptor tyrosine-based activating motifs [52,53]. In humans,
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13 genes and 2 pseudogenes coding for KIR molecules have been identified. An additional step of KIR
heterogeneity is given by the high number of polymorphisms of these molecules (1110 different KIR
polymorphisms currently identified in the IPD-KIR Database, release 2.9.0).
KIRs are clonally expressed on NK cells, meaning that each cell expresses a different set of KIRs,
determined randomly. Only cells expressing at least one KIR (or the heterodimer CD94/NKG2A)
that recognizes self-HLA undergo “education” and become licensed [54]. Indeed, the higher the
binding of iKIRs to their ligands during NK-cell maturation is, the higher the cytotoxicity of the
cell is. Conversely, a high binding of aKIRs to their ligands leads to a lower cytotoxicity [55].
Generally, NK cells recognize and kill cells that do not express or express low levels of ligands for their
iKIRs. This mechanism is defined as “missing self-hypothesis” and it is the reason why NK cells are
fundamental in tumor immunosurveillance.
Of note, the interaction between KIR and HLA-I may act as promoter (aKIR) or dampen (iKIR) for
a phenotype change. In particular, the highly cytotoxic CD56dim KIR+ NK cells, can acquire surface
CCR7 upon interaction with CCR7+ cells, becoming able to migrate in response to the secondary
lymphoid-tissue chemokines CCL19/CCL21. This novel NK-cell ability occurs through a trogocytosis
mechanism and precedes the NK-mediated cytolysis [56–59].
Specifically, NK cells are fundamental for recognizing tumors downregulating HLA-I molecules
in order to escape from T cells [53] Reversely, for tumor cells that do not loose HLA-I, iKIRs can be
considered as additional IC that aid the immunoevasion of the transformed cells. For this reason,
numerous immunotherapies based on mAbs blocking iKIR-HLA interactions have been developed to
unleash NK cells against HLA-I+ tumor cells, thus increasing the potential activity of these cytotoxic
innate effectors (Table 1).
The first anti-pan-KIR2D developed, lirilumab (Innate Pharma) [34], is included in at least thirteen
clinical trials (4 Phase-I, 5 Phase-II, 4 Phase-I/II) with two studies terminated [both Phase II trials, one was
terminated because of the sponsor’s decision not to pursue the development of lirilumab for myeloid
malignancies (NCT02599649), the other was terminated because of the response rates not meeting
the anticipated minimum of 30% (NCT02399917)]. Of these studies six are on solid tumors, six on
hematological malignancies and one is on all pediatric tumors. Although lirilumab is well tolerated
for doses up to 10 mg/kg in monotherapy, unfortunately monotherapy with lirilumab did not show
significative results, thus its effects are now mostly studied in combination with other ICIs, especially
nivolumab (anti-PD-1, 7 clinical trials). A clinical trial, completed on 11 August 2020, studying the
effect of lirilumab in combination with nivolumab and with nivolumab and ipilimumab (anti-CTLA-4)
in patients with advanced solid tumors, was presented in a press release. The combination of lirilumab
and nivolumab in squamous cell carcinoma of the head and the neck (SCCHN) patients (n = 29) was
well-tolerated and resulted in an objective response rate of 24%, with durable response (NCT03341936).
Lirilumab is currently under study also in combination with elotuzumab (anti-CS1, NCT02252263)
or rituximab (anti-CD20, NCT02481297) in multiple myeloma (MM), and with nivolumab or lirilumab
and ipilimumab, together with other drug combinations, in MM, HL, and non-Hodgkin (NHL)
lymphomas (Phase I/II trial, NCT01592370).
In addition to mAbs targeting KIRs, alternative strategies to target the KIR/HLA-I axis are
under investigation. As an example, a miRNA (miR146a-5p) targeting KIR2DL1/KIR2DL2 mRNA
by abrogating their expression has been recently identified [60,61]. This result may be exploited
to generate/increment the effect of NK-cell KIR-mismatching against HLA-I+ tumor cells and thus
improve the NK-mediated anti-tumor activity.
2.3. NKG2A
NKG2A is an inhibitory receptor that, together with its activating counterpart NKG2C, belongs to
the C-type lectin receptor family. It is expressed in association with CD94 on almost 50% of the NK
cells in the PB [62].
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The CD94/NKG2 complexes recognize the non-classical HLA-E molecule, expressed in most
human tissues and displaying signal peptides derived from leader peptide sequences of other HLA-I
molecules [63,64] or HCMV [65]. The engagement of CD94/NKG2A leads to the phosphorylation of
their ITIM, resulting in an inhibitory signal that suppresses competing signals from NKG2C [63,66,67].
Under physiological conditions, this mechanism provides an important “self-signal” to allow
self-tolerance and to prevent the destruction of self-bystander cells.
In human cancer, while classical HLA alleles are frequently lost to prevent T-cell recognition [68],
HLA-E expression is even upregulated, as a protective mechanism of cancer cells against immune
surveillance and elimination by cytotoxic lymphocytes [69]. Indeed, IFN-γ secreted by immune cells
during anti-tumor immune responses upregulates the expression of HLA-E on tumor cells [70,71].
High levels of HLA-E have been reported in several cancer types, including NSCLC [72],
glioblastoma [73], melanoma, breast (BC) [74], liver [75], kidney [76], gynecological [77], and colorectal
cancers [78,79].
In turn, the overexpression of HLA-E on cancer cells drives the upregulation of CD94/NKG2A on
cytotoxic lymphocytes, including NK cells, in both hematological and solid tumors [80]. In fact,
tumor-infiltrating NK cells have higher expression of NKG2A than non-tumoral NK cells in
NSCLC [81,82], BC [83], and OC [84]. Moreover, a direct correlation between levels of HLA-E
expression and those of NKG2A and CD94 in tumor-infiltrating lymphocytes has been observed [80].
The binding of CD94/NKG2A to HLA-E/peptide on tumor cells results in the inhibition of the
effector-functions of NK cells [85] and of other cytotoxic lymphocytes, thus leading to a poor prognosis
in various solid cancers [74,78]. Likewise, phenotypic abnormalities have been reported also in NK cells
from patients affected by hematologic malignancies. Indeed, PB NK cells from acute myeloid leukemia
(AML) patients show impaired effector functions and an upregulation of NKG2A accompanied by
decreased expression of NKp46 [86].
These data highlight an important role of the NKG2A/HLA-E axis in preventing the activation
of cytotoxic NK cells in the tumor microenvironment, thus making NKG2A a suitable targetable
checkpoint to unleash NK-cell-mediated responses against HLA-E+ tumor cells.
As a matter of fact, a mAb against NKG2A (IPH2201, monalizumab) has been developed by
Innate Pharma (Marseille, France) in partnership with AstraZeneca (Cambridge United Kingdom) [36]
and it is now employed in various trials for the treatment of different tumors (reviewed in [87]). In this
regard, a phase I clinical trial (NCT02459301) in patients with advanced, recurrent, or metastatic
gynaecologic cancers has been completed and shows that monalizumab administration leads to
short-term stabilization with minimal treatment toxicities and excellent treatment tolerance [35].
Moreover, since preclinical studies showed that anti-NKG2A in combination with anti-PD-L1
mAbs has a synergistic effect on tumors expressing both HLA-E and PD-L1 [36], several clinical
trials are now investigating the effectiveness of monalizumab in combination with other compounds,
including anti-PD-L1 (NCT02643550, NCT03822351, NCT04145193, NCT03833440, NCT02671435,
NCT03794544), anti-EGFR (NCT02643550), and anti-Bruton’s tyrosine kinase (NCT02557516) [5,88]
(Table 1).
In the context of hematologic malignancies, we recently described in patients undergoing a
haploidentical hematopoietic stem cell transplantation (haplo-HSCT) the early expansion of anergic
donor-derived NK-cell subpopulation expressing high levels of NKG2A [10]. Ongoing studies are now
investigating whether the administration of monalizumab, early after haplo-HSCT, can restore the
NK-cell cytotoxicity thus improving engraftment and limiting the onset of opportunistic infections and
the occurrence of acute graft versus host disease [87].
In addition to mAbs targeting NKG2A, alternative strategies to target the NKG2A/HLA-E axis are
under investigation. As an example, a construct containing a fragment derived from an anti-NKG2A
antibody linked to endoplasmic reticulum-retention domains, has been developed to abrogate NKG2A
expression [80].
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2.4. TIM-3
T-cell immunoglobulin and mucin domain 3 (TIM-3) is an inhibitory receptor able to recognize
several ligands. In particular, TIM-3 binds galectin-9, which is upregulated in various cancers and
chronic infections [89–94], causing the apoptosis of Th1 cells [95]. The TIM-3 variable IgV domain
has also been reported to bind high mobility group protein B1 and this binding compromises the
activation of immune responses. In addition, TIM-3 recognizes phosphatidylserine (PtdSer) [89,90] and
carcinoembryonic antigen cell adhesionmolecule 1 (Ceacam-1). PtdSer is over-expressed in apoptotic
cells and induces the clearing of apoptotic bodies and the reduction of antigen cross-presentation by
dendritic cells (DCs) [74,96], while the interaction between TIM-3 and Ceacam-1 is involved in T-cell
exhaustion promotion, thus suggesting that the inhibitory function of TIM-3 depends on Ceacam-1
co-expression [97].
TIM-3 expression is quite spread among immune cells, indeed CD4+, CD8+ and regulatory (Treg)
T cells, B cells, NK cells, NKT cells, and myeloid cells may be TIM-3+ [90,98]. TIM-3 engagement with
its ligands induces immune tolerance by exhausting T cells as well as NK cells [39,92,99,100].
Regarding NK cells, TIM-3 is highly expressed in resting NK cells as compared to the CD56+
NKT and CD56+ T cells [101]. Its expression is mainly restricted to the CD56dim subset and
may be upregulated on CD56bright cells upon cytokine stimulation [101,102]. High frequencies
of circulating and/or tumor infiltrating TIM-3+ NK cells have been found in different types
of malignant tumors [38,40,103] including gastric cancer (GC) [38], lung adenocarcinoma [39],
advanced melanoma [40], and bladder cancer [38–41]. Importantly, while the increased surface
levels of TIM-3 on NK cells in cancers induce NK-cell impairment [41], the in vitro and ex vivo TIM-3
blockade results in increased NK-cell cytotoxicity [39,40,104]. Contrariwise, studies have also reported
stimulatory functions of TIM-3 [105]. These divergent functions are likely associated with the existence
of multiple and different TIM-3 ligands.
Co-expression of TIM-3 and PD-1 was shown to mediate the exhaustion of CD8+ T cells in
various cancers and chronic viral infections [106–110]. On the contrary, clear data about a possible
co-expression of TIM-3 and PD-1 on NK cells are not yet available. In this context, anti-TIM3
antibodies, including Sym023, cobolimab, LY3321367, BGB-A425, and MBG453, in combination with
several anti-PD-1/PD-L1 antibodies, are under clinical investigation for their efficacy against various
cancers. Sym023 has been developed and is being tested in phase I clinical trials, in patients with
advanced and metastatic solid tumor malignancies or lymphomas refractory to currently available
therapies, in monotherapy or in combination with anti-PD-1 or anti-LAG-3 antibodies (NCT03489343
and NCT03311412). Additional phase I studies of anti-TIM-3 antibodies have been initiated in
patients with advanced solid tumors, as a monotherapy or in combination with an anti-PD-1 antibody
(NCT02817633, NCT03680508, NCT04139902, NCT03680508, NCT03744468). Relatlimab (BMS-986016
TSR-022, Tesaro Inc, Waltham, MA, United States) is under investigation in three clinical trials in
advanced cancer alone or in combination with anti-PD-1 (NCT02817633, NCT03307785), and in primary
liver cancer in combination with anti-PD-1 (NCT03680508). MBG453 (Novartis) is being evaluated as
monotherapy or in combination with anti-PD-1 in patients with advanced malignancies (NCT02608268)
and patients with AML or high-risk myelodysplastic syndromes (NCT03066648) (Table 1).
2.5. TIGIT
T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) is an immune inhibitory
receptor of T and activated NK cells. TIGIT competes with the activating receptor DNAM-1 for binding
PVR and Nectin-2 [111]. Upregulation of both TIGIT and its ligands have been described in multiple
cancer types. TIGIT expression on NK cells, and the consequent exhaustion of these cells, has recently
been described in colon cancer patients and tumor models [42]. Moreover, the expression of PVR was
shown to correlate with a diminished tumor infiltration and with increased VEGF expression and
increased angiogenesis [112]. TIGIT expression was proven to suppress both NK and CD8+ T-cell
function in CRC growth [42].
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Conversely to CTLA-4 and PD-1, TIGIT was associated to NK-cell exhaustion in a mouse model
of colon cancer and TIGIT blockade was capable of reverting the condition allowing NK cells to trigger
an anti-tumor immune response. TIGIT blockade was proven to synergize with anti-PD-L1 antibody
therapy helping memory immunity in tumor rechallenge models [42].
In hematological tumors, TIGIT was suggested as a biomarker in the context of allogeneic HSCT,
because of its correlation with a diminished NK-cell count in the bone marrow (BM) after transplant.
Thus, TIGIT blockade was suggested as a potent strategy to increase graft versus leukemia effect in
allogeneic HSCT in AML [43].
Because of the rapid consolidation of TIGIT as an important player in immuno-escape, numerous
anti-TIGIT mAbs are currently being tested for clinical use. In this regard, tiragolumab (Genetech/Roche,
South San Francisco, CA, United States) is currently under investigation together with atezolizumab
(anti-PD-1) on cervical cancer (NCT04300647), esophageal squamous cell carcinoma (NCT04543617),
small cell lung cancer (NCT04256421), NSCLC (NCT04513925, NCT03563716), esophageal cancer
(NCT04540211, NCT03281369), advanced liver cancer (together with the anti-VEGF bevacizumab,
NCT04524871), urothelial carcinoma (NCT03869190), pancreatic adenocarcinoma (NCT03193190),
and advanced metastatic tumors (NCT02794571). Moreover, BMS-986207 (Bristol-Myers Squibb,
New York, NY, United States) is being tested as a single agent in MM (NCT04150965) and as a single
agent or together with nivolumab on advanced solid tumors (NCT04570839).
Etigilimab (OncoMed Pharmaceuticals, Redwood City, CA, United States) was tested together with
nivolumab in a single trial that was terminated because of the decision of the sponsor (NCT03119428);
AB154 (Arcus Bioscience, Hayward, CA, United States ) is being tested alone and together with
zimberelimab (anti-PD-1) in advanced solid tumors (NCT03628677) and in lung cancer (NCT04262856)
(Table 1).
2.6. LAG-3
Lymphocyte activation gene-3 (LAG-3) is a member of the immunoglobulin superfamily receptors
with inhibitory properties [113]. LAG-3 is a negative co-inhibitory receptor mainly expressed on T
and NK cells, but also on other immune cells including tumor infiltrating lymphocytes (TILs), Treg,
iNKT cells, B cells, and DCs [89,114–119]. It recognizes MHC class II (MHC-II) molecules (with greater
affinity than CD4) [113,120,121], the C-type lectin receptor LSECtin, and a fibrinogen-like protein1
(FGL1) on target cells [120,122,123].
Engagement of LAG-3 promotes T-cell exhaustion [124–126] and the suppressive activity of
Treg [116,127]. In addition, LAG-3 synergizes with PD-1 in T-cell functional regulation to promote
tumor immune escape [128]. LAG-3 has been shown to suppress immune responses in several tumors,
including HL, GC, BC [111] and its blockade restores T-cell functions [125]. On the other hand,
its specific role in regulating NK-cell function is still not fully clarified and recent findings suggest that
LAG-3 is expressed on “adaptive” NK cells chronically exposed to HCMV rather than on activated NK
cells [129,130].
Nevertheless, LAG-3 is currently considered a good target for immunotherapy in order to
strengthen not only T-cell anti-tumor activity, but also the NK cell once probably through ADCC.
In this context, different anti-LAG-3 antibodies [i.e., relatlimab (BMS-986016)] are currently being
used in phase I and phase II clinical trials as single drugs in metastatic cancers, solid tumors
and lymphoma (NCT03489369), or in association with other ICIs, including, anti-TIGIT in
MM (NCT04150965), with or without anti-PD-1 antibodies in treating patients with advanced
NSLCC (NCT02658981), solid tumors (NCT01968109, NCT03470922, NCT02720068, NCT03250832,
NCT02460224, NCT03365791), and hematologic malignancies (NCT03365791, NCT03598608), advanced
malignancies (NCT03005782) including SCCHN (NCT04080804), triple-negative BC (NCT03499899),
and metastatic melanoma (NCT03484923). A number of additional LAG-3 antibodies are currently in
preclinical development (Table 1).
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In addition, a soluble recombinant LAG-3-Ig fusion protein, Eftilagimod alpha (IMP321), has been
used as an immunological adjuvant for vaccination against various infections and cancer. It has
been employed as monotherapy or combined with chemotherapy in cancer (NCT02676869) [45],
in metastatic BC (NCT00349934), in patients with melanoma (NCT01308294) and with PD-1 in SCCHN
(NCT03625323).
IMP321 was able to induce cytokine production (IFN-γ and/or TNF-α) by NK cells in PBMCs from
HDs and, to a lower extent, in PBMCs from 21 untreated metastatic cancer patients in a short-term
ex vivo assay [131]. In metastatic renal cancer patients, IMP321, in a dose-escalation study (P003),
induced NK-cell activation as monotherapy [132]. In BC patients IMP321, associated with standard
chemotherapy, induced an enhanced NK-cell activation for several months [133].
Hence, LAG-3 has the potential to activate T cells as well as NK cells and it can be further explored
as a potential target for checkpoint inhibition.
3. Helper ILCs
NK cells being the innate counterparts of CD8+ T cells, helper ILCs are viewed as mirrors of CD4+
T helper cells. Despite many shared patterns, we and others also identified distinct regulatory circuits
of ILC and T helper by comparing their transcriptomic profiles [134–137]. Of note, transcripts encoding
for ICs are less abundant in human resting ILCs than in CD4+ T-helper cells, eventually contributing to
their ability to swiftly respond to external stimuli in an antigen-independent manner. Upon activation,
a dynamic modulation of inhibitory receptor expression occurs to ensure proper termination of the
response and resolution of inflammation. However, while the role of checkpoint molecules has been
largely explored in T-cell responses, only recent studies have started to uncover the involvement of ICs
in tuning helper ILC-dependent immunity, including in anti-tumor responses.
3.1. PD-1
PD-1 was initially described as a marker of ILC progenitors [137,138]. Single-cell RNA-seq analysis
on Lin-Flt3lo/−IL-7Rαlo/+α4β7+ BM cells revealed a cluster of ILCs expressing Pdcd1 (encoding for
PD-1) together with Id2, Tcf7, Tox, and Gata3. Differently from T cells, the ILCs belonging to this
cluster did not express other inhibitory or activation molecules. Isolated PD-1hi ILCs, transferred
in vivo or individually seeded in vitro, differentiated in all the ILC subsets, without generating B
or T cells, demonstrate that PD-1 expression identified unipotent and pluripotent ILC progenitors.
A deeper analysis showed that only the PD-1hi ILCs, also positive for Bcl11b and IL-25R, were able to
differentiate exclusively into ILC2s, defining IL-25R as a marker of early ILC2 progenitors in PD-1hi
cells. However, also a certain percentage of peripheral terminally differentiated ILCs expressed PD-1
and, upon influenza infection or papain challenge, proliferated and secreted high amount of IL-13
and IL-5. On the contrary, Taylor et al. [139] showed that PD-1+KLRG1+ ILC2s had a proliferative
disadvantage in comparison to PD-1−KLRG1+ ILC2s. This result, however, was not confirmed by
Batyrova et al. [140], who reported no difference in KLRG1+ ILC2s between Rag1−/− and Pdcd1−/−
xRag1−/− mice.
Some differences in the experimental models could explain the dichotomies observed in these first
publications. First of all, Taylor et al. [139] used Pdcd1−/− mice that were not used by Yu et al. [137],
and Batyrova et al. [140]. used Rag1−/− as background for all the experiments. Taylor et al. [139] and
Batyrova et al. [140], moreover, focused on KLRG1+ ILC2s and helminth infection, differently from
Yu et al. [137], that were not restricting their analysis to the ILC2s expressing KLRG1 and that were
using influenza infection and papain challenge. In addition, while Taylor et al. [139] identified in IL-33
the trigger for PD-1 expression and Batyrova et al. [140] in PPAR-γ agonists, Yu et al. [137], did not
determine the signals inducing the PD-1+ ILC progenitor. Another interesting point is that, in the
model of Taylor, after 3 days of stimulation, ILC2s started to upregulate PD-L1. It is therefore possible
that the PD-1/PD-L1 interaction on different ILC2s could influence their proliferation and function
leading to different results overtime.
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PD-1 expression on ILC2s is modulated by cytokines. A cascade involving TNFα-induced
IL-33 secretion by pre-adipocytes was shown to induce PD-1 expression in adipose tissue ILC2s in
obese mice. As a consequence, PD-L1highM1 macrophages triggered PD-1 on ILC2s in models of
high-fat diet-induced obesity, leading to ILC2 dysfunction and limiting type-2 mediated tissue beiging.
Therapeutic blockade of PD-1 in these animals partially restored ILC2 functions and ameliorated
the metabolic homeostasis [141]. In line with these findings, Helou et al. [142] reported that PD-1 is
inducible on pulmonary ILC2s upon intranasal IL-33 stimulation. By comparing the transcriptomic
profiles of pulmonary ILC2s from WT and PD-1 knockout mice the authors highlight an in cis
interaction between PD-1 and PD-L1 in IL-33 activated ILC2s. This binding, as well as an in trans
PD-1/PD-L2 engagement, is responsible for the impaired ILC2 cytokine secretion and survival that
mechanistically occurs at least in part through a metabolic switch. Indeed, deficiency of PD-1 resulted
in the upregulation of glycolysis-dependent genes and in the increase of amino acid degradation,
showing for the first time a PD-1-dependent metabolic inhibition of ILC2 proliferation. By developing
and testing a PD-1 agonist in a humanized mouse model of house dust mite-induced asthma the
authors demonstrate the potential of PD-1 inhibition of ILC2s in asthma treatment.
Beside ILC2s, PD-1 is also expressed by human group 3 ILCs in the decidua [17]. During the
first trimester of pregnancy, CD56+ ILC3s and CD56− ILC3s (also referred as lymphoid tissue inducer
(LTi-like cells) expressed PD-1 and TIM-3 (see also below), but not LAG-3 and TIGIT. PD-1 expression
limited the ILC3 cytokine production and decreased after the first trimester. Because intermediate
extravillous trophoblast (iEVT) and decidual stromal cells express PD-L1, the presence of PD-1+ ILC3s
during the first trimester could contribute to the feto-maternal tolerance. This speculation is supported
by the fact that, in samples obtained from spontaneous abortion, PD-L1 expression in iEVT was much
lower than in normal pregnancies. However, this new mechanism of immune-tolerance would need to
be confirmed and analyzed in in vivo models.
3.2. PD-1 Expression on ILCs in Cancer
Salimi et al. were the first in documenting the expression of ICs (i.e., PD-1 and CTLA-4) in ILCs
present in human tumor tissues [24]. They observed no difference in the expression of PD-1 in ILCs
present in malignant versus benign BC tissues. However, the level of PD-1 in tumor-associated ILC2s
was higher in comparison with the circulating ILCs. Interestingly, in gastrointestinal tumors, ILC2s and
ILC3s express higher PD-1 than in the perilesional tissue. This phenotype was partially associated
with an increase in HLA-DR, KLRG1, CD69, and CD44, and with a decrease in CCR7 expression.
Whether PD-1+ILCs in tumor tissues are more activated or exhausted is yet to be determined.
Subsequently, the analysis of the innate cell compartment of patients presenting human-malignant
pleural effusion revealed an infiltration by all the ILC subsets, with a prevalence of PD-1+ ILC3s [29].
By activating these cells through their natural cytotoxicity receptors (NCR, i.e., NKp30, NKp44 and
NKp46), the authors showed that a small proportion (2.5–6% of NCR+ ILC3s) could produce IFN-γ and
TNF-α. Interestingly, by using an anti-PD-1 antibody or a recombinant PD-L1 molecule, the production
of IFN-γ and TNF-α was inhibited, suggesting that, in the tumor microenvironment, the anti-tumor
activity of ILC3s could be repressed because of their PD-1 expression.
In another work, Wang et al. identified six ILC subsets by performing single-cell RNA sequencing
to profile tumor-infiltrating ILCs in an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced
colitis-associated colorectal cancer (CRC) model [33]. Among those, three subsets expressed ILC2
signature genes (ILC2-A, -B, and -C). The ILC2-C subpopulation expressed high PD-1 and HS3ST1
(heparan sulfate3-O-sulfotransferase 1). Because of several elegant experiments, among which are
the transfer of PD-1highILC2s in B-NSG mice, the deletion of PD-1 and HS3ST1 from ILC2s by
CRISPR-Cas9 technology, the generation of Hs3st1flox/floxId2-CreERT2 mice, the targeting of PD-1 with
an anti-PD-1 antibody, Wang et al. demonstrated that PD-1+ and HS3ST1+ ILC2s are involved in CRC
tumor progression.
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Further, Moral and colleagues dissected a synergistic effect of anti-PD1 blockade targeting both
anti-tumor ILC2s and CD8+ T cells in pancreatic ductal adenocarcinoma (PDAC) [143]. The authors
reported on abundant infiltration of human and murine PDAC by ILC2s. In mice, these cells were
induced by in situ-secreted IL-33 to release CCL5, recruiting CD103+ DCs that in turn promoted the
priming of cytotoxic CD8+ T cells. Of note, as previously reported by others, IL-33 induced PD-1
expression on ILC2s, and combined administration of recombinant IL-33 and anti-PD-1 antibodies
acted synergistically in sustaining ILC2 anti-tumor functions and in restoring CD8+ T-cell cytotoxicity.
This resulted in significant tumor size reduction and prolonged animal survival. As a correlate,
PD-1+ ILC2s were detected in human PDAC and IL-33 mRNA transcripts correlated with improved
survival in patients with PDAC (Table 1).
Further work is needed to decipher the implication of PD-1 in pro- or anti-tumor functions of
ILC2s in cancer and to define the impact of anti-PD-1 immunotherapy on ILC2s.
3.3. CTLA-4
In steady state conditions, CTLA-4 transcripts are poorly present in ILCs and cell surface protein
is almost undetectable in human ILCs [135]. Salimi et al. reported the expression of CTLA-4 in
tumor-associated ILC1s and ILC2s, being higher in comparison with the circulating ILCs, while no
difference was observed in malignant versus benign BC tissues [24]. Gao and colleagues observed
in different murine tumor models higher expression of CTLA-4 in intermediate ILC1s (intILC1s,
being CD49a+CD49b+EOMES+), that are impaired in their ability to secrete IFN-γ but not TNF-α [144]
(Table 1). The excess of TNF-α and the secretion of VEGF by ILC1s might be linked to pro-tumoral
and pro-angiogenic phenomena. However, the mechanism(s) of regulation of cytokine secretion by
CTLA-4 in ILCs remains to be elucidated.
3.4. TIGIT and CD96, and TGF-β
Beside their expression on conventional NK cells, TIGIT and CD96 are also found on ILC1s and
splenic ILC3s [46]. While TIGIT targeting on NK cells, either alone or in combination with other
ICs, leads to the restoration of anti-tumor activities [42], the functional consequence of TIGIT and/or
CD96 blockade on ILCs remains unknown. Using different tumor mouse models, Gao et al. [144]
reported that the intratumoral TGF-β mediates the conversion of anti-cancer NK cells into intermediate
ILC1s (CD49a+CD49b+Eomes+) and ILC1s (CD49a+CD49b−Eomesint). This shift was accompanied
by an upregulation of TIGIT and CD96, and concomitant reduction in DNAM-1 levels, thus creating
a pro-tumor environment [144]. Besides its effect on NK-ILC1 plasticity, TGF-β signaling was also
reported to drive ILC3 conversion into ILCs with a regulatory phenotype [33]. Indeed, Wang et al. [33]
showed that during CRC progression, the proportion of ILC3s was decreased by concomitant expansion
of Id3+ IL-10 secreting cells. Using either Tgfbr2flox/floxId2-CreERT2 mice to delete the TGF-β receptor
on ILCs or a TGF-β inhibitor, the conversion was inhibited and the tumor growth suppressed. This data
suggested that the interference with the TGF-β signaling could be considered as a targetable checkpoint
to fire at tumor infiltrating ILCs [44] (Table 1).
3.5. KLRG1
The C-type lectin KLRG1 is expressed by a subset of ILC2s, in vivo expanded by IL-25
administration, involved in anti-helminth responses and called “inflammatory” ILC2s [145].
KLRG1 ligation to E-Cadherin in vitro leads to ILC2 functional impairment with decreased IL-5
and IL-13 secretion [47], while its in vivo relevance remains unexplored. Interestingly, KLRG1 was
also found to be expressed in a small percentage in ILC3s present in lymphocytes isolated from
first-trimester decidual tissues [17] (Table 1). However, the role of these KLRG1+ ILC3s has not been
elucidated yet. In cancer, KLRG1 transcripts have been identified in ILC2s in lung and CRC [20].
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3.6. TIM-3
TIM-3+ human ILC3s were found in the decidua, to be inhibited in their IL-22 production upon
TIM-3 cross-linking [17] (Table 1). Differently from PD1+ ILC3s, TIM-3+ ILC3s did not decrease after
the first-trimester of pregnancy. Also in this case, in vivo experiments in animal models could provide
more insights into the role of TIM-3+ ILC3s present at the feto-maternal interface. Nothing is known to
date on the role of this type 1 glycoprotein on ILCs in cancer settings.
3.7. LAG-3
Expression of LAG-3 in resting ILCs has not been reported yet. As compared to their adaptive
counterparts Th17 cells, that express LAG-3 to some extent, ILC3 were reported to be LAG-3
negative [135]. However, ILC3 are involved in a 3-cell party regulation dependent on LAG-3+
Tregs. In that axis, LAG-3+ Tregs, interacting with MHC-II on CX3CR1+ intestinal tissue-resident
macrophages, restrained their secretion of IL-23 and IL-1β. As a consequence, the lack of a supportive
environment reduced ILC3 activation and secretion of IL-22, thus suppressing colitis [146].
Moreover, Gao et al. reported that upon conversion from NKs to ILC1s in tumors,
several checkpoints were upregulated, among them LAG-3, reaching much higher levels than
on conventional NKs [144] (Table 1).
3.8. NKG2A
Another checkpoint molecule expressed by ILCs is NKG2A. We showed that, in humans,
a population of Lin-CD127+CD56+c-Kit− ILC1-like ILCs is present in HD and in AML patients [37].
In HDs, these cells are able to kill tumor cells in a KIR-independent manner, while in AML this ability
was impaired. The ILC1-like ILCs isolated from AML patients expressed lower levels of TRAIL,
NKp30, and NKp80 than the ones from HD. However, they expressed high levels of the CD94/NKG2A
heterodimer (up to 80%) that, upon engagement with HLA-E on leukemic targets, resulted in decreased
degranulation and impairment of ILC cytotoxic functions. Whether targeting NKG2A in AML patients
with monalizumab would result in a more efficient killing of the leukemic target by the ILC1-like ILCs
is still to be determined.
Additionally, along with the induction of LAG-3, KLRG1, and CTLA-4 on TGF-β-induced ILC1s,
NKG2A is also overexpressed during the conversion from NK cells. Yet, its functionality has not
been investigated, but decreased functionality of converted ILC1s is most likely due to checkpoint
upregulation [144]. However, it remains to be determined if these cells express the CD94/NKG2A
heterodimer able to deliver inhibitory signals upon HLA-E engagement, similarly to NK cells.
3.9. Metabolic Checkpoints
Beside the conventional IC presented above, a novel ILC2-dependent metabolic immune
checkpoints has recently been uncovered [147]. The authors show that pre-existing type2 inflammation
in the lung favors metastatic seeding, in an IL-33 and ILC2-dependent manner. ILC2s were driving
the local IL-5-dependent eosinophil accumulation that correlated with impaired NK-cell activities.
Mechanistically, eosinophils can suppress NK-cell functions by extracellular glucose deprivation
and lactic acid increase, thus impairing the NK-cell glycolysis-dependent effector functions. In this
context it has been shown that the NK/eosinophil cross-talk is regulated by the interaction of NCRs
with eosinophil surface ligands [148]. Future work is needed to determine how to target these novel
metabolic checkpoints to reinvigorate anti-tumor immunity, either alone or in combination with the
conventional ICI.
4. Conclusions
It is now evident that ICI have provided an historical step forward in our multi-year effort to fight
oncological diseases. Pioneer studies showed T cells as the main actors of these successes, but it is now
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clear that also NK cells may represent an excellent cancer immunotherapy tool because of their ability
to kill malignant cells without toxicity toward healthy cells. This is clinically relevant for patients with
tumors displaying a T-cell-resistant (HLA-Ineg) phenotype. In this context, the ICI specific for NK
cells, such as monalizumab and lirilumab, aimed at NKG2A and KIR inhibitory receptors respectively,
have been assessed as monotherapy, and have shown good safety profiles, but mild success in terms of
prolonging progression-free survival. This result is not completely surprising, because of the complexity
of immuno-regulatory mechanisms and the heterogeneity of malignancies. Thus, future clinical trials
will have to reveal the potency of these NK-cell ICI in combination with other cancer treatment options.
Importantly, the combinations of ICI, such as CTLA-4 and PD-1 inhibitors, that are being tried for
synergistic response targeting T cells could also be tried in the context of NK cells. In this regard,
it has recently been shown that PD-1 receptor is not only expressed by NK cells, but it has been also
demonstrated that PD-1 and PD-L1 inhibitors are able to enhance NK-cell-mediated cytotoxicity [26].
Similarly, the anti-NKG2A mAb monalizumab can boost CD8+ T-cell as well as NK-cell immunity.
Hence, a combination of a PD-1 or PD-L1 inhibitor and a NK-cell-specific checkpoint inhibitor (such
as an anti-KIR or anti-NKG2A mAb), could be of value for combined checkpoint inhibition-based
immunotherapy. Thus, an eye should be kept on the ongoing clinical trials exploiting this kind of
new combinations.
It is also worth considering that despite all steps forward, immune checkpoint blockade therapies
are not always effective, and even responding patients may subsequently relapse. Thus, the need of a
deeper monitoring of cytotoxic lymphocytes (T and NK cells) in the tumor microenvironment and
of their IC expression and interplay is needed to develop more effective treatments. In this regard,
another strategy might be to call in our aid helper ILCs. Indeed, while the role of checkpoint molecules
has been largely explored in cytotoxic lymphocytes, only recently studies have started to uncover
the involvement of immune checkpoints in fine-tuning ILC-dependent immunity. In this context,
several studies show that IC molecules may play an important role also in ILCs in anti-tumor responses.
Although, as of today, there are no ILC therapies ongoing, we already know that targeting ILCs in AML
using monalizumab would be beneficial to unleash the cytotoxicity of ILC1-like cells. Based on the
pre-clinical observations of Moral et al. [143], PD-1 targeting on ILC2s might be beneficial in pancreas
adenocarcinoma. Similarly, this strategy might activate ILC3s, as suggested by Tumino et al. [29].
In contrast to that, this same therapeutic strategy might be detrimental in settings where ILC2s exert
pro-tumoral functions. Indeed, the administration of anti-PD-1 might favor ILC2 activity and increase
the secretion of pro-tumoral Type-2 cytokines, supporting tumor growth [144]. Thus, additional studies
on checkpoint expression in ILCs are needed to define optimal ILC targeting strategy.
Overall, we believe that, in our near future, immunotherapy protocols will need to be designed
taking into account all ILCs, both cytotoxic (NK) and non-cytotoxic (helper ILCs) ones, and most
importantly, ILC targeting should be tailored according to the disease (Figure 1).
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